GlaxoSmithKline plc will increase supplies of its Infanrix hexa (DTPa, hep B, IPV, Hib) paediatric combination vaccine to Europe.
Infanrix hexa is recommended for co-administration with Wyeth's 7-valent pneumococcal vaccine Prevenar.
Infanrix hexa was approved in the European Union on 23 October 2000 and is currently marketed in 9 Member States (Austria, Belgium, France, Germany, Greece, Italy, Luxembourg, Spain and Sweden). Worldwide it is authorized in a further 42 countries, including Iceland and Norway.
Jean Stéphenne, President of GSK Biologicals said, "We are already preparing shipments of sufficient supplies of Infanrix hexa to the European markets affected by this recommendation and we are working with the authorities to ensure their rapid release."
Recently, the European Medicines Agency (EMEA) has suspended the Marketing Authorisation for Hexavac vaccine (DTPa, hep B, IPV, Hib) of Sanofi Pasteur MSD as a precautionary measure.